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increased circulating catecholamines (CAs).
Initially an adaptive process to compensate for
decreased function following cardiac injury
through stimulation of β-adrenergic receptors
(βARs), SNS activation becomes maladaptive,
contributing significantly to disease morbidity and
mortality (3-5). Levels of norepinephrine (NE) are
associated with worsened prognosis in HF (6).
Epinephrine (Epi) and, to a lesser extent, NE
secretion from the adrenal medulla provides
essentially all circulating CAs and is a
fundamental component of SNS outflow (7,8).
Chronic CA elevation in the heart causes
significant dysregulation of βARs that include a
myriad of molecular abnormalities (9). Included is
the up-regulation of G protein-coupled receptor
kinase 2 (GRK2 or βARK1), which contributes
significantly to βAR and ventricular dysfunction
(4,5).
α2ARs play a crucial role in autocrine
feedback inhibition of CA release from cardiac
sympathetic nerve terminals and from the adrenal
medulla. In the latter tissue, they reside in
membranes of chromaffin cells, which are
responsible for adrenal CA production (10,11).
The importance of α2AR-mediated SNS activity
regulation in cardiac disease has been well
documented in a variety of knockout (KO) mouse
models (12-14), and in HF patients (15,16). We
recently reported that, in addition to myocardium,
GRK2 is up-regulated in the adrenal gland in
animal models of HF, leading to enhanced CA
release via desensitization/downregulation of the
chromaffin cell α2ARs (17). We also showed that
adrenal GRK2 inhibition via adenoviral-mediated
in vivo gene therapy using the βARKct (a GRK2
inhibitory peptide) (18) acutely decreases
circulating CAs and improves cardiac inotropic
reserve and function (17).
In the present study, we posited that
adrenal-targeted GRK2 gene deletion, before the
onset of HF, might be beneficial by reducing
sympathetic activation. To specifically delete
GRK2 in the chromaffin cells of the adrenal gland,
we took advantage of the Cre/loxP technology (19)
and crossed PNMTCre mice, expressing Cre
recombinase under the gene promoter of the
chromaffin
cell-specific
enzyme
phenylethanolamine
N-methyl
transferase
(PNMT) (20), with floxed GRK2+/+ mice (21). In

Chronic heart failure (HF) is characterized
by sympathetic overactivity and enhanced
circulating catecholamines (CAs), which
significantly increase HF morbidity and
mortality. We recently reported that adrenal G
protein-coupled receptor kinase 2 (GRK2) is
up-regulated in chronic HF, leading to
enhanced
CA
release
via
desensitization/downregulation
of
the
chromaffin cell α2-adrenergic receptors
(α
α2ARs) that normally inhibit CA secretion.
We also showed that adrenal GRK2 inhibition
decreases circulating CAs and improves
cardiac inotropic reserve and function. Herein,
we hypothesized that adrenal-targeted GRK2
gene deletion before the onset of HF might be
beneficial by reducing sympathetic activation.
To specifically delete GRK2 in the chromaffin
cells of the adrenal gland, we crossed
PNMTCre mice, expressing Cre recombinase
under
the
chromaffin
cell-specific
phenylethanolamine
N-methyl
transferase
(PNMT) gene promoter, with floxedGRK2
mice. After confirming a significant (~50 %)
reduction of adrenal GRK2 mRNA and protein
levels, the PNMT-driven GRK2 knockout (KO)
offspring underwent myocardial infarction
(MI) to induce HF. At 4 weeks post-MI, plasma
levels of both norepinephrine and epinephrine
were reduced in PNMT-driven GRK2 KO,
compared to control mice, suggesting markedly
reduced post-MI sympathetic activation. This
translated in PNMT-driven GRK2 KO mice
into improved cardiac function and dimensions
as well as amelioration of abnormal cardiac
βAR signaling at 4 weeks post-MI. Thus,
adrenal-targeted
GRK2
gene
knockout
decreases circulating CAs, leading to improved
cardiac function and β -adrenergic reserve in
post-MI HF. GRK2 inhibition in the adrenal
gland might represent a novel sympatholytic
strategy that can aid in blocking HF
progression.
Despite recent advances in prevention and
management of heart disease, death due to chronic
heart failure (HF) continues to rise and new and
innovative treatments are needed (1,2). A salient
feature of HF is elevated sympathetic nervous
system (SNS) activity and outflow, reflected by
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order to induce HF, resultant mice homozygous
for the floxed allele (i.e. PNMTCre+//floxedGRK2+/+) and control mice with
endogenous
GRK2
expression
underwent
myocardial infarction (MI) and were studied at 4
weeks post-MI.
Our data demonstrate that
reduction of circulating CAs via adrenal-targeted
GRK2 gene deletion can improve cardiac function
and βAR signaling post-MI and this sympatholysis
in beneficial in HF.

performed using the α2AR-specific antagonist
[3H]-rauwolscine. Data were analyzed by
nonlinear regression analysis using GraphPad
Prism (GraphPad Software).
Cardiac βAR density and cAMP measurementsβAR density was measured in isolated cardiac
125
plasma
membranes
using
I-CYP
(Iodocyanopindolol), as described (23). Cardiac
cAMP levels were measured with the BIOMOL
Cyclic AMP PLUS EIA kit (Biomol, Plymouth
Meeting, PA), as described (23).
Statistical analysis- Data are summarized as
mean±SEM. Comparisons were made using t tests
or ANOVA as appropriate. A Bonferroni
correction was applied to the probability values
whenever multiple comparisons arose. Values of
P<0.05 were considered significant.

Experimental Prodecures
Mouse generation, PCR screening and real-time
PCR- Screening for the presence of the PNMTCre transgene was done in genomic tail DNA from
transgenic mice by PCR using a specific primer
mix, as described (20). Real-time RT-PCR was
carried out as described (17).
Western blotting- Western blotting was performed
in protein extracts of whole adrenal glands and
hearts using appropriate specific antibodies, as
described (17).
Surgical MI- All animal procedures and
experiments were performed in accordance with
the guidelines of the Institutional Animal Care and
Use Committee of Thomas Jefferson University.
MI was induced by high ligation of the left
anterior descending coronary artery, as described
previously (22).
Plasma and in vitro CA measurements- Plasma
norepinephrine and epinephrine were determined
with the BI-CAT EIA kit from ALPCO
Diagnostics (Windham, NH), as described (17).
Echocardiographic
and
hemodynamic
measurements- Two-dimensional guided M-mode
and Doppler echocardiography, and closed chest
cardiac catheterization were performed in mice as
described (17,22).
Chromaffin cell culture and in vitro CA secretion
assays- Chromaffin cells were isolated from
adrenal glands excised from the mice and cultured
as described previously (17). The purity of
cultured chromaffin cells was assessed
morphologically and by immunofluorescence
and/or immunoblotting for endogenous expression
of tyrosine hydroxylase; purity was over 90% in
all experiments.
α2AR density measurements- Plasma membranes
from excised adrenal glands were prepared as
described (17), and saturation binding was

RESULTS
Generation of PNMT-driven GRK2 KO mice.
PNMT-driven GRK2 KO mice were generated by
crossing the PNMT-Cre and the floxed GRK2+/+
mouse lines and breeding the offspring to floxed
allele homozygosity. All the mice used in the
present study were heterozygous for the PNMTCre allele and homozygous for the floxedGRK2
allele (PNMTCre+/-/floxGRK2+/+). PCR screening
in tail genomic DNA confirmed the presence of
the PNMT-Cre allele in the offspring (Fig. 1A).
GRK2 gene deletion induced by adrenal
chromaffin cell expression of Cre recombinase led
to a significant (53.1±0.5 %) reduction of total
adrenal GRK2 mRNA levels in the PNMT-driven
GRK2 KO mice compared to control wild-type
(WT) floxed GRK2+/+ mice (Fig. 1B). Of note,
total adrenal mRNA levels of GRK3 and GRK5,
the two most important of the other ubiquitously
expressed GRKs (4), were unchanged (data not
shown), confirming the specificity of this genetic
deletion approach as well as the fact that it did not
cause any compensatory changes in the levels of
other adrenal GRKs when GRK2 was lost.
Importantly, western blotting of total adrenal
protein extracts from PNMT-driven GRK2 KO
and WT mice confirmed a significant loss (~50%)
of GRK2 protein consistent with the loss of GRK2
gene expression in only the chromaffin cells (Fig.
2A&B).

3

signaling/function in these cells, thus providing
proof of concept for the generation of these mice.
Levels of post-MI HF sympathetic activation
in PNMT-driven GRK2 KO mice. We have
previously reported that adrenal GRK2 is an
important regulator of adrenal CA secretion and
hence of circulating CA levels, both in normal
animals and in HF (17,24). Thus, we investigated
the impact of GRK2 loss in chromaffin cells on
circulating plasma CA levels. We measured CA
levels in PNMT-driven GRK2 KO and WT mice
under basal conditions (using Sham-operated
mice) and also 4 weeks after surgically induced
MI. Interestingly, plasma levels of both NE and
Epi were similar between Sham WT and PNMTdriven GRK2 KO mice (Fig. 4). This is consistent
with the reported finding that mono-allelic Cre
insertion into the PNMT locus does not result in
changes of the levels of either catecholamine (20).
Indeed, plasma levels of both NE and Epi were
similar between the control WT floxedGRK2+/+
used in this study and PNMT-Cre+/- mice (data not
shown). Following MI (4 weeks), we found that
overall survival post-MI was similar in both
groups of mice (data not shown), however, we
found a significant difference in plasma CAs 4
weeks post-MI as both NE and Epi levels were
significantly lower in PNMT-driven GRK2 KO
mice compared to WT mice (Fig. 4). This result
strongly suggests that PNMT-driven GRK2
deletion results in significant attenuation of postMI sympathetic activation/increased outflow.
In vivo cardiac function 4 weeks after MI. We
next investigated the impact of reduced post-MI
circulating CA levels in PNMT-driven GRK2 KO
mice on the development of cardiac dysfunction.
As shown in Fig. 5A, cardiac ejection fraction (EF
%) is significantly increased in KO mice
compared to WT mice (>10% improvement) at 4
weeks post-MI whereas both groups of shamoperated animals exhibited similar EF % values.
Further, post-MI left ventricular (LV) remodeling
was slightly but significantly attenuated in KO
mice compared to WT mice as indicated by the
reduction of LV end-diastolic diameter (LVEDD)
(Fig. 5B). Additionally, in vivo cardiac
catheterization of these mice at 4 weeks post-MI
revealed markedly decreased basal and
isoproterenol-induced cardiac contractility in both
groups compared to sham animals (Fig. 5C).
Importantly, although basal +dP/dtmax responses

Adrenal phenotypic characterization of
PNMT-driven GRK2 KO mice. After confirming
the success of GRK2 gene deletion in CAproducing chromaffin cells, we investigated the
adrenal phenotype of PNMT-driven GRK2 KO
mice. First, PNMT-driven GRK2 KO mice are
viable, reproduce normally and present without
any significant abnormalities. Previously, we have
found that in HF, adrenal GRK2 up-regulation is
accompanied by significant adrenal hypertrophy
and elevated CA biosynthetic activity, as reflected
by tyrosine hydroxylase (TH) upregulation, the
enzyme that catalyzes the rate limiting step in CA
biosynthesis (7,8). Therefore, we measured
adrenal size and TH expression in adult (twomonth-old) PNMT-driven GRK2 KO and WT
mice. We found that chromaffin cell GRK2
deletion leads to a significant decrease of adrenal
size (Fig. 2C & Table 1). In addition, adrenal TH
is down-regulated to a similar extent (~50 % at the
protein level) in 2-month-old PNMT-driven GRK2
KO mice compared to age-matched control WT
mice (Fig. 2A&B). A full outline of the overt
phenotypic features of these mice can be found in
Table 1. Taken together, these results suggest that
chromaffin cell GRK2 deletion leads to
attenuation of adrenal growth and CA biosynthetic
activity during development.
Adrenal α2AR signaling status in PNMTdriven GRK2 KO mice. We also investigated the
impact of chromaffin cell-targeted GRK2 deletion
on the signaling status of the sympatho-inhibitory
α2ARs, which regulate CA secretion from these
cells (8,10). Saturation ligand binding in plasma
membranes from the adrenal glands of PNMTdriven GRK2 KO mice revealed a significant
upregulation of α2ARs compared to age-matched
control WT mice (Fig. 3A). Consistent with this,
in vitro CA secretion assays in chromaffin cells
isolated and cultured from the adrenals of these
mice showed that, in cells derived from PNMTdriven GRK2 KO`s, the α2AR agonist UK14304 is
capable of producing a larger (maximal) inhibition
of nicotine-induced CA secretion compared to WT
mouse-derived chromaffin cells (Fig. 3B). Taken
together, these experiments confirm that the
absence of GRK2 from the chromaffin cells of
PNMT-driven GRK2 KO mice leads to increases
in both functional α2AR number and α2AR
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were similar between PNMT-driven GRK2 KO
and WT mice post-MI, PNMT-driven GRK2 KO
mice had significantly improved responsiveness to
isoproterenol compared to post-MI WT mice (Fig.
5C).
Of note, LV infarct size was similar between
the two groups at 24 hrs post-MI (Fig. 6), and also
at 4 weeks post-MI (data not shown), indicating
that this improvement in cardiac function observed
in PNMT-driven GRK2 KO`s at 4 weeks post-MI
was not due to differences in initial myocardial
damage caused by the coronary artery ligation or
in viable/functional myocardial mass between the
two groups. Table 2 provides a complete outline of
the in vivo echocardiographic and hemodynamic
parameters of the sham and 4-week post-MI HF
mice within both groups. Taken together, the
above physiological data suggest that cardiac
function and β-adrenergic-stimulated inotropic
reserve at 4 weeks post-MI are significantly
improved by the reduction in circulating CA levels
due to the chromaffin cell-targeted GRK2
deletion. In other words, there is less cardiac
dysfunction 4 weeks post-MI when CA levels are
decreased due to a loss of adrenal GRK2
expression.
Myocardial β-adrenergic signaling status at 4
weeks post-MI. We also examined whether the
observed improvement in cardiac function of postMI PNMT-driven GRK2 KO mice translated into
positive alteration of cardiac βAR signaling at the
molecular level, since lower sympathetic overdrive
during HF progression could mean less βAR
desensitization and downregulation. Accordingly,
hearts from both sham-operated and HF mouse
lines were excised at 4 weeks post-MI, and total
βAR density in plasma membranes isolated from
these hearts was measured. As expected, HF
caused a marked cardiac βAR down-regulation in
both mouse lines at 4 weeks post-MI, compared to
healthy sham animals (Fig. 7A). However, in postMI failing KO hearts this βAR down-regulation
was significantly attenuated compared to control
WT hearts (Fig. 7A). In addition, we also
measured total steady-state 3`, 5`-adenosine
monophosphate (cAMP) levels in these hearts.
cAMP is a second messenger activated by
myocardial βARs crucial for their pro-contractile
signaling (3,4). As shown in Fig. 7B, myocardial
cAMP levels in HF control WT hearts were

significantly reduced compared to sham hearts,
consistent with impaired βAR signaling in HF.
Cardiac cAMP levels of HF PNMT-driven GRK2
KO mice however were essentially restored to the
levels of sham hearts (Fig. 7B), indicating a
marked amelioration of cardiac βAR signaling in
adrenal-targeted GRK2-depleted mice at 4 weeks
post-MI. It is important to note that the levels of
cAMP in PNMT-driven GRK2 KO hearts were
not elevated above sham (non-failing) heart levels
and that levels appear to be normalized (Fig. 7B).
Finally, we measured myocardial GRK2
levels and found that GRK2 was significantly
increased in HF control WT hearts, again as
expected (Fig. 7C&D).
Interestingly, GRK2
levels in PNMT-driven GRK2 KO hearts, albeit no
different from WT hearts in sham healthy animals,
were markedly reduced at 4 weeks post-MI
compared to WT hearts at the same time-point, to
even below the levels of sham hearts (Fig. 7C&D),
suggesting a complete prevention and/or reversal
of the contractility-suppressive cardiac GRK2 upregulation in failing PNMT-driven GRK2 KO
hearts. Taken together, these results indicate that
the reduction of catecholaminergic stimulation of
the failing heart by the adrenal-specific GRK2
deletion significantly ameliorates myocardial βAR
number, signaling and function, which probably
underlies, in turn, the improvement in cardiac
function.
Cardiac
remodeling
and
functional
biomarkers at 4 weeks post-MI. To further analyze
morphological and molecular aspects of adverse
cardiac remodeling, we also assessed mRNA
expression levels of specific genes known to play
important roles in HF pathogenesis. The heart
weight-to-body weight (HW/BW) ratio was
significantly increased in control WT mice at 4
weeks post-MI compared to the sham groups
consistent with a HF phenotype, while cardiac
mass was significantly decreased in PNMT-driven
GRK2 KO mice 4 weeks after MI (Table 2). For
molecular LV remodeling and hypertrophy status
characterization, we measured the mRNA levels of
collagen 1 (Col-1), atrial natriuretic factor (ANF)
and transforming growth factor-β1 (TGFβ1) in the
LV of all groups via RT-PCR. Consistent with the
echocardiographic data presented above (Fig. 5),
Col-1, ANF and TGFβ1 mRNA levels were
markedly increased in control WT hearts at 4
weeks post-MI, as expected, and levels of these
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detrimental cardiac markers were significantly
reduced in PNMT-driven GRK2 KO hearts over
the same post-MI time-period (Fig. 8A-C). These
results demonstrate that the reduction of cardiac
sympathetic activation by the adrenal-specific
GRK2 deletion results in significant attenuation of
post-MI HF-related remodeling. Finally, mRNA
levels of brain natriuretic peptide (BNP), a fetal
gene marker of cardiac hypertrophy, HF and
volume overload, were measured. Levels of BNP
were again markedly elevated in control WT
hearts at 4 weeks post-MI as expected, whereas
KO hearts showed significantly lowered BNP
expression (Fig. 8D). This favorable change in
BNP levels is entirely consistent with the
echocardiographic and hemodynamic analysis
results presented above (Fig. 5 and Table 2). Of
note, the adrenal hypertrophy present in WT mice
after MI, as expected (17), appears significantly
attenuated in PNMT-driven GRK2 KO mice at 4
weeks post-MI, as well (Table 2).

Previously, GRK2 was found, by tightly
regulating the activity and function of the
sympatho-inhibitory α2ARs of the adrenal gland
and of the central SNS, to be a key regulator of the
CA levels present at the heart at any given time,
and hence of the levels of cardiac
catecholaminergic stimulation, which is an
important factor affecting morbidity and mortality
in HF (6,9). Moreover, we have shown that
adrenal GRK2 inhibition via adenoviral-mediated
in vivo gene therapy acutely decreases circulating
CAs and improves cardiac inotropic reserve and
function in rats with already established HF (10
weeks post-MI) (17). With the data from the
current study, it is now even clearer that lowered
GRK2 expression and activity in the adrenal gland
can have a significant beneficial impact on the
injured heart by imparting a sympatholytic effect
on CA secretion from the adrenal medulla.
Importantly, the PNMT-driven GRK2 KO
mice appear viable and normal and present no
gross phenotypic abnormalities. Interestingly, with
regard to their adrenal phenotype, they appear to
have significantly reduced CA biosynthetic
activity, as reflected by the down-regulation of TH
present in their adrenals. In addition, the size of
their adrenals is reduced compared to WT animals
at two months of age (Table 1), and, intriguingly,
they also display significantly attenuated adrenal
hypertrophy at 4 weeks post-MI (Table 2). Thus,
adrenal GRK2 seems to be an important trophic
factor for the adrenal gland in health, but also a
major driving force behind adrenal hypertrophy
and hyperfunctioning in HF. These findings are
also consistent with the up-regulation of adrenal
TH and the enhanced adrenal hypertrophy
observed in HF rats, where adrenal GRK2 is also
up-regulated, and also with the reduction of
adrenal TH levels of HF rats observed when
adrenal GRK2 is inhibited in vivo (17). In
addition, GRK2 emerges as a critical regulator of
adrenal CA biosynthetic function in general, with
its activity driving the organ towards increased
production of CAs. The mechanisms for this are
not clear at the moment. It could very well be an
indirect mechanism, i.e. increased GRK2 leads to
enhanced CA secretion which in turn forces the
adrenal medulla to produce more CAs to meet the
growing demand, but GRK2 might also be more
directly involved in adrenal CA biosynthesis, e.g.
via regulation of specific biosynthetic enzymes. In

DISCUSSION
In previous studies, we documented a
crucial role for adrenal GRK2 in regulation of
cardiac sympathetic stimulation, both under
normal conditions and in the context of chronic
HF (17,24, and reviewed in 11). In the present
study, we sought to investigate whether
suppression of adrenal GRK2 before the onset of
HF can confer any benefit in progressing post-MI
HF by reducing cardiac sympathetic burden. To
this end, we developed a new transgenic mouse
model having the GRK2 gene specifically deleted
in the chromaffin cells of the adrenal medulla
(PNMT-driven GRK2 KO), by utilizing the well
established Cre/loxP technology (19), and we
induced chronic HF by surgical MI in these mice.
Our findings show that adrenal-restricted GRK2
deletion indeed leads to a significant reduction of
circulating CAs in vivo in post-MI HF, thus
proving the concept of the transgenic animal
approach employed, and, importantly, this
resultant reduction of both circulating CAs (NE
and Epi) appears indeed to impede the
deterioration of cardiac function and βAR
signaling which are hallmarks of the post-MI
chronic HF progression.
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any case, the mechanisms of this relationship of
GRK2 with CA biosynthetic function in the
adrenal gland will be of great interest to study and
will be the focus of future studies.
Perhaps the most important finding of the
present study is that adrenal-targeted GRK2
deletion causes a substantial reduction in
circulating CAs post-MI, although it does not
affect CA levels in normal, sham-operated mice.
This finding confirms that the genetic
perturbations employed to create this PNMTdriven GRK2 KO line did not have any nonspecific, non-adrenal GRK2-related effects on
circulating CAs. More importantly, it also strongly
suggests that adrenal GRK2 is absolutely crucial
for the elevation of CA levels in post-MI HF, and
thus, inhibition/suppression of adrenal GRK2
activity early on after the occurrence of an MI can
have a powerful sympatholytic effect, which is
very beneficial in the post-MI HF setting (9,25).
Admittedly, the reduction in circulating
CAs conferred by adrenal-specific GRK2 deletion
in the present study appears relatively small,
perhaps smaller than might have been expected,
bringing circulating CA levels nowhere near the
normal (sham) values. However, this can be
explained by the fact that, in the PNMT-driven
GRK2 KO model described here, GRK2 is deleted
only in Epi-producing cells and tissues, not in
every sympathetic tissue in the body (20).
Therefore, sympathetic neurons can still produce
and release NE normally. On the other hand, NE
can still normally stimulate βARs present in
central (or other) adrenergic/sympathetic neurons,
which facilitate NE and/or Epi release (26); thus,
even Epi might not be substantially reduced by the
GRK2 deletion in adrenal chromaffin cells.
Therefore, when all these parameters are taken
into account, the unchanged (with respect to wild
type) CA levels in normal (sham) PNMT-driven
GRK2 KO mice and the relatively small CA level
reductions in these mice observed post-MI are not
all that surprising. Nevertheless, even slight
reductions in the catecholaminergic burden of the
failing heart can have profound beneficial effects
on cardiac function and overall clinical status of
the HF patient (27). In fact, excessive plasma CA
reduction has been postulated to actually be
deleterious rather than beneficial in HF patients
(27,28). Thus, it is absolutely plausible that the
reductions in circulating CAs we observed in the

PNMT-driven GRK2 KO mice can significantly
impact cardiac function and βAR signaling postMI in a beneficial manner.
The final interesting finding of the present
study is the observed down-regulation of GRK2 in
the failing hearts of PNMT-driven GRK2 KO
mice. Since myocardial GRK2 critically regulates
cardiac βAR signaling and function and hence
cardiac performance and its up-regulation post-MI
is a major contributor to the functional worsening
of the failing heart (3,4,5,23), this finding is
reflective of the improved cardiac βAR signaling
and function induced by CA reduction in the HF
PNMT-driven GRK2 KO mice. However, it
additionally suggests a close dynamic regulation
of myocardial GRK2 activity by the levels of
cardiac catecholaminergic activation (23,29),
which in turn are tightly regulated by GRK2
activity in the adrenal glands and in the central
SNS (11,17). Thus, the findings of the present
study reinforce the notion that GRK2 is a key
molecule in fine-tuning cardiac function, both
basally and after sympathetic stimulation, and in
particular in circumstances where this function is
severely compromised, such as in the chronic HF
setting (11).
Overall, the present study reports that
adrenal-targeted GRK2 gene deletion helps halt
progression of cardiac contractile dysfunction and
adverse remodeling and restores the abnormalities
of cardiac βAR signaling in post-MI chronic HF
by
significantly
reducing
circulating
catecholamine levels after cardiac injury, which
are extremely toxic for the failing heart (6,25). Of
note, the beneficial effects of adrenal-specific
GRK2 deletion also include down-regulation of
cardiac GRK2, an important indicator of cardiac
dysfunction in HF, and are evident even without a
dramatic reduction in CA levels, which could be
detrimental for cardiac hemodynamic support of
the circulation and incompatible with life (27,28).
Thus, reduction of sympathetic activity/outflow
via adrenal GRK2 inhibition as early as possible in
the course of post-MI HF progression emerges as
an attractive therapeutic strategy in the
management of LV dysfunction.
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FIGURE LEGENDS
Fig. 1. (A) PCR screening in tail genomic DNA from PNMTCre/FloxedGRK2 (PNMTCre/Flox) or
control FloxedGRK2 (Flox) mice for confirmation of PNMT locus insertion of the Cre transgene. An
additional lane run without DNA (H2O), thus serving as negative control for the assay is also shown. (B)
Real time PCR in total adrenal mRNA isolated from two-month-old PNMT-driven GRK2 KO or control
FloxedGRK2 (WT) mice for determination of total adrenal GRK2 mRNA levels. *, p<0.05, n=6
mice/litter.
Fig. 2. (A) Representative western blots in total adrenal protein extracts from 2-month-old PNMT-driven
GRK2 KO or control FloxedGRK2 (WT) mice for total adrenal GRK2 or Tyrosine Hydroxylase (TH)
protein levels. Blots for the housekeeping protein glyceraldehyde 3-phosphate dehydrogenase (GAPDH),
as loading control, are also shown. (B) Densitometric quantitation of the 4 independent experiments done
in (A) using GAPDH levels as normalization control. *, p<0.05, vs. WT, n=4 independent experiments
performed in extracts from 6 adrenals pooled from 3 mice/litter each. (C) Adrenal weight-to-body

weight (AW/BW) ratios of these mice (see also Table 2). *, p=0.023, n=10 mice/litter.
Fig. 3: (A) Plasma membrane α2AR density in the adrenal glands of 2-month-old PNMT-driven GRK2
KO or control FloxedGRK2 (WT) mice. Non-specific binding was determined in the presence of 0.4 mM
phentolamine. *, p<0.05, vs. WT, n=3 independent experiments, performed with 8 adrenals pooled from 4
mice/litter each. Data are expressed as mean ± s.e.m. (B) In vitro catecholamine secretion from
chromaffin cells isolated from these mice after nicotine treatment, following pretreatment with vehicle
(Nicotine) or with 10 µM UK14304 (UK14304 + Nicotine). UK14304 pre-treatment alone had no effect
(data not shown). *, p<0.05, vs. WT/Nicotine, **, p<0.05, vs. WT/UK14304 + Nicotine, n=3 independent
experiments, performed with cells isolated from 10 adrenals pooled from 5 mice/litter each.
Fig. 4. Plasma circulating norepinephrine and epinephrine levels in normal, sham-operated (Sham) or in
4-week post-MI HF (MI) PNMT-driven GRK2 KO (PNMT GRK2 KO) and control FloxedGRK2 (WT)
mice. *, p<0.05, vs. Sham-either genotype, **, p<0.05, vs. WT MI, n=6 mice/group.
Fig. 5. (A) Ejection fraction (EF %) of sham-operated (sham) or of 4-week post-MI HF (MI) PNMTdriven GRK2 KO (PNMT GRK2 KO) and control FloxedGRK2 (WT) mice. *, p=0.005, vs. WT MI,
n=10 mice/group. (B) Left Ventricular End Diastolic Diameter (LVEDD) of these mice. *, p<0.05, vs.
sham, **, p<0.05, vs. WT MI, n=10 mice/group. (C) Basal and maximal dose of isoproterenol (Max. Iso)stimulated +dP/dtmax responses of these mice. *, p<0.05, vs. sham, **, p<0.05, vs. Max. Iso/MI WT, n=7
mice/group.
Fig. 6: Infarct size in PNMT-driven GRK2 KO (KO) and WT mice at 24 hrs post-MI. Sham hearts are
also shown as negative controls. (A) Representative triphenyltetrazolium chloride (TTC)–stained cardiac
cross-sections. (B) Average left ventricular (LV) infarct size (n=5 for each group). No significant
difference between the MI groups was observed (p=0.05).
Fig. 7. (A) βAR density in cardiac plasma membranes of sham-operated (sham) or of 4-week post-MI HF
(MI) PNMT-driven GRK2 KO (KO) and control WT mice. *, p<0.01, vs. either Sham, **, p<0.05 vs. MI
WT, n=6 hearts/group. (B) Steady-state total cAMP levels in cardiac homogenates purified from hearts
of these mice. *, p<0.05 vs. all other groups, n=6 hearts/group. (C) Representative western blots in total
cardiac protein extracts from these mice for cardiac GRK2 protein levels. Blots for the housekeeping
protein glyceraldehyde 3-phosphate dehydrogenase (GAPDH), as loading control, are also shown. (D)
Densitometric quantitation of the blots done in (C), using GAPDH levels as normalization control. *,
p<0.05, vs. respective Sham, n=6 hearts/group.
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Fig. 8. Heart mRNA levels of (A) collagen I (Col1); (B) atrial natriuretic factor (ANF); (C) transforming
growth factor β1 (TGFβ1); (D) brain natriuretic peptide (BNP) in all experimental groups at 4 weeks
post-MI. All values were standardized to amplified 28S rRNA. Data are presented as mean ± SEM and
plotted as fold of sham WT values. *, p<0.05, vs. MI WT, n=6 hearts/group.
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Table 1: Basic phenotypic characteristics of 2-month-old male WT and PNMT-driven
GRK2 KO mice

WT

PNMT-driven GRK2 KO

Heart weight

140+ 5.0 mg

136+ 4.0 mg

Adrenal weight

2.5+ 0.2 mg

1.6+ 0.3 mg*

Body weight

27.8+ 0.9 g

26.9+ 1.0 g

Liver weight

2.1+ 0.2g

2.2+ 0.2 g

Lung weight

175+ 13 mg

181+ 11 mg

Kidney weight

630+ 71 mg

645+ 75 mg

*, p<0.05 vs. WT, n=10. Note: The basic cardiac functional parameters of these mice are
presented in Table 2 (see columns for Sham/WT and Sham/KO of Table 2).
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Table 2: Cardiac functional parameters in sham and post-MI WT and PNMT-driven
GRK2 KO mice

Sham/WT

Sham/KO

post-MI/WT

post-MI/KO

LVIDs (mm)

2.34±0.08

2.32±0.11

4.39±0.12#

3.31±0.21#,*

LVIDd (mm)

3.88±0.15

3.96±0.08

4.99±0.12#

4.69±0.06#,*

FS (%)

38.52±0.14

39.25±2.39

13.77±1.13#

20.11±0.35#,*

EF (%)

69.6±1.97

70.12±3.02

30.90±1.65#

41.17±0.97#,*

PWTd (mm)

0.95±0.05

1.00±0.02

1.28±0.01#

1.11±0.04#,*

Basal Hemodynamic Measurements
HR (min–1)

468.2±2.9

477.6±11.5

457.6±12.5

456.3±8.7

+dP/dtmax

5,430±29

5,432±49

4,552±63#

4,448±75#

-5,159±206

-5,041±101

-4,379±104#

-4,298±57#

LVESP (mmHg)

98.4±1.1

98.8±1.86

83.43±4.4#

86.14±1.8#

LVEDP (mmHg)

3.8±0.4

4.0±0.4

11.2±0.8#

10.7±1.4#

(mmHg/s)

–dP/dtmin
(mmHg/s)

Hemodynamic Measurements after maximal Isoproterenol (333 ng/kg BW)
HR (min–1)

576±17.2

581±7.2

578±13.3

582±7.1

+dP/dtmax

9,717±740

10,451±230

6,689±328#

8,273±489#,*

-8,456±438

-8,380±255

-6,557±392#

-6,647±318#

LVESP (mmHg)

101±2.3

101±1.8

86±3.1#

89±3.4#

LVEDP (mmHg)

4.8±1.4

4.6±0.6

12.4±0.9#

12.25±0.5#

(mmHg/s)

–dP/dtmin
(mmHg/s)
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Phenotypic data:
HW/BW (mg/g)

5.03±0.18

5.06±0.13

9.8±0.32#

8.2±0.09#,*

AW/BW (mg/g)

0.09±0.01

0.06±0.01+

0.38±0.06#

0.19±0.03#,*

Echocardiographic and hemodynamic analysis data from 3-month-old sham-operated (Sham) or
post-MI WT and PNMT-driven GRK2 KO mice on day 28 post-MI. +dP/dtmax, maximal first
derivative of LV pressure rise; –dP/dtmin, minimal first derivative of LV pressure fall; HR, heart
rate; LVESP, LV end systolic pressure; LVEDP, LV end diastolic pressure; LVIDd, LV inner
diameter during diastole; LVIDs, LV inner diameter during systole; FS, fractional shortening;
EF, ejection fraction; PWTd, posterior wall thickness in diastole; HW/BW: Heart weight-to-body
weight ratio; AW/BW: Adrenal weight-to-body weight ratio; LV: Left ventricular; #, p<0.05 vs.
either sham line, *, p<0.05 vs. post-MI/WT, and +, p<0.05 vs. Sham/WT, n=10 mice/group for
echo, HW/BW and AW/BW measurements, n=7 mice/group for hemodynamic measurements.
ANOVA with Bonferroni test were performed among all groups. Data are presented as mean ±
SEM.
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